Abstract |
Autologous hematopoietic stem cell transplantation (ASCT) is a well-established treatment strategy in HIV-related lymphoma patients (HIV+ Ly). Nevertheless, current evidence is mainly based on reports from specialized centers, multicentre heterogeneous studies, noncomparative analyses, or registry data-based comparisons. Likewise, the risk of infections reported so far for this population, seems to be similar to that of HIV- patients, and it does not seem to impact on mortality. We report a single-center retrospective comparative analysis of AHCT procedural results, infectious complications and survival in HIV+ Ly matched with a non-HIV comparative cohort. Thirty-three HIV+ patients and 45 matched controls, who underwent ASCT between 2000 and 2016, were included. Transplant-related toxicity, event-free survival, relapse rate, and overall survival were similar in both groups. Engraftment was delayed in HIV+ Ly (neutrophils: 15 vs 12 days (p = 0.0001), and platelets 39 vs 16 days (p = 0.00001)). Bacterial infections during the pre-engraftment period were more frequent in HIV+ Ly (RR 2.24, p = 0.017), as well as viral infections in the postengraftment period (RR 3.22, p = 0.004). CMV reactivation was more frequent in HIV+ Ly (39% vs 15% p = 0.007). In conclusion, ASCT is viable and effective in HIV+ Ly, but it is associated with a higher risk of infection.
|
Authors | Mariana Bastos-Oreiro, Pascual Balsalobre, Pilar Miralles, Juan Berenguer, Nieves Dorado, Rebeca Bailen, Gillen Obreoscoa, Javier Anguita, David Serrano, José Luis Díez-Martín, Mi Kwon |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 55
Issue 9
Pg. 1716-1725
(09 2020)
ISSN: 1476-5365 [Electronic] England |
PMID | 32132653
(Publication Type: Journal Article)
|
Topics |
- HIV Infections
(complications)
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma
(complications, therapy)
- Neoplasm Recurrence, Local
- Retrospective Studies
- Stem Cell Transplantation
- Transplantation, Autologous
|